- Home
- JSPR vs CGTX Comparison
JSPR vs CGTX Comparison
Compare JSPR & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- CGTX
- Stock Information
- Founded
- JSPR 2018
- CGTX 2007
- Country
- JSPR United States
- CGTX United States
- Employees
- JSPR 64
- CGTX N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- JSPR Health Care
- CGTX Health Care
- Exchange
- JSPR Nasdaq
- CGTX Nasdaq
- Market Cap
- JSPR 47.6M
- CGTX 53.4M
- IPO Year
- JSPR N/A
- CGTX 2021
- Fundamental
- Price
- JSPR $2.86
- CGTX $1.67
- Analyst Decision
- JSPR Buy
- CGTX Strong Buy
- Analyst Count
- JSPR 12
- CGTX 3
- Target Price
- JSPR $30.78
- CGTX $2.83
- AVG Volume (30 Days)
- JSPR 293.2K
- CGTX 8.4M
- Earning Date
- JSPR 08-13-2025
- CGTX 08-07-2025
- Dividend Yield
- JSPR N/A
- CGTX N/A
- EPS Growth
- JSPR N/A
- CGTX N/A
- EPS
- JSPR N/A
- CGTX N/A
- Revenue
- JSPR N/A
- CGTX N/A
- Revenue This Year
- JSPR N/A
- CGTX N/A
- Revenue Next Year
- JSPR N/A
- CGTX N/A
- P/E Ratio
- JSPR N/A
- CGTX N/A
- Revenue Growth
- JSPR N/A
- CGTX N/A
- 52 Week Low
- JSPR $2.27
- CGTX $0.22
- 52 Week High
- JSPR $26.05
- CGTX $1.97
- Technical
- Relative Strength Index (RSI)
- JSPR 42.31
- CGTX 78.08
- Support Level
- JSPR $2.90
- CGTX $1.40
- Resistance Level
- JSPR $3.14
- CGTX $1.97
- Average True Range (ATR)
- JSPR 0.20
- CGTX 0.21
- MACD
- JSPR 0.09
- CGTX 0.09
- Stochastic Oscillator
- JSPR 71.03
- CGTX 78.78
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.